Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-03-07
2003-10-14
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017400, C514S016700, C514S449000
Reexamination Certificate
active
06632795
ABSTRACT:
BACKGROUND OF THE INVENTION
Cancer is a disease for which many potentially effective treatments are available. However, due to the prevalence of cancers of various types and the serious effects it can have, more effective treatments, especially those with fewer adverse side effects than currently available forms of treatment, are needed.
SUMMARY OF THE INVENTION
This invention relates to pharmaceutical compositions useful in treating cancer in a mammal. The pharmaceutical compositions of the present invention comprise two compounds: a first compound which is paclitaxel, taxotere or a modified taxane or taxoid analog and a second compound, which is a compound of Formula I:
R
1
R
2
N—CHX—CO—A—B—D—(E)
s
—(F)
t
—(G)
u
—K (I)
Formula I is discussed in detail below. Some examples of compounds of Formula I are specifically presented herein. For example, compounds of Formula I can be those in which R
1
and R
2
are each methyl or ethyl; X is isopropyl, sec-butyl or tert-butyl; s is 1; t and u are each 0; A is valyl, isoleucyl or 2-tert-butylglycyl; B is N-methylvalyl, 1-isoleucyl or 2-tert-butylglycyl; D is thiazolidinylcarbonyl, 3,4-dehydroprolyl or prolyl; E is prolyl, thiazolidinyl-4-carbonyl, homoprolyl, hydroxyprolyl or 3,4-dehydroprolyl; and K is a substituted amino moiety having the formula R
5
—N—R
6
, wherein R
5
is hydrogen or C
1
-C
4
-alkoxy and R
6
is a monovalent radical such as (1)- or (2)-adamantyl; (CH
2
)v-phenyl with v=1; &agr;,&agr;-dimethylbenzyl; a C
1
-C
12
linear or branched hydroxyalkyl group, such as —C(CH
3
)
2
—CH
2
—CH
2
—OH, also referred to as 3-hydroxy-1,1-dimethylpropyl; a C
3
-C
10
cycloalkyl group, such as bicyclo[3.3.0]octa-1-yl, 1-methylcyclopentyl or 1-methylcyclohexyl; or a C
1
-C
12
linear or branched alkyl group, such as
—C(CH
3
)
3
, also referred to as tert-butyl;
also referred to as 1,1-dimethylpropyl;
also referred to as 1-methyl-1-ethylpropyl;
also referred to as (S)- or (R)-1-methyl-2,2-dimethyl-propyl;
also referred to as (S)- or (R)-1-ethyl-2-methylpropyl;
also referred to as 1-isopropyl-2-methylpropyl; or
—C(CH
3
)
2
—CH(CH
3
)
2
, also referred to as 1,1-dimethyl-2-methylpropyl;
—CH(CH
3
)
2
, also referred to as isopropyl;
—CH(CH
3
)CH
2
CH
3
, sec-butyl [(S) or (R)]; or
—CH(CH
3
)CH(CH
3
)
2
, also referred to as 1,2-dimethylpropyl.
Each compound is present in the pharmaceutical composition in an effective amount. The pharmaceutical composition can include one or more of each type of compound (e.g., one or more of the first type of compound, such as paclitaxel or paclitaxel and taxotere and one or more compounds of Formula I).
This invention also relates to methods of treating cancer in a mammal in which the pharmaceutical compounds described herein are used. In the method of the present invention, the two compounds are administered in the pharmaceutical composition or as individual/separate compounds which are given sufficiently close in time to have the desired effect.
It has been discovered that, surprisingly the combination of paclitaxel, taxotere or a modified taxane or taxoid analog as described herein and a compound having Formula I as described herein provides enhanced or therapeutically synergistic anticancer effects in vivo. For purposes of this invention, two drugs are considered therapeutically synergistic if a combination regimen produces a significantly better tumor cell kill than the best constituent when it is administered alone at optimal or maximum tolerated doses. Differences in tumor cell kill less than half a decade are not considered signficant.
REFERENCES:
patent: 4816444 (1989-03-01), Pettit et al.
patent: 4879278 (1989-11-01), Pettit et al.
patent: 5227400 (1993-07-01), Holton et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Ueda et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5484612 (1996-01-01), Brown
patent: 5494930 (1996-02-01), Shimizu et al.
patent: 5502032 (1996-03-01), Haupt et al.
patent: 5504191 (1996-04-01), Pettit et al.
patent: 5525613 (1996-06-01), Wynn et al.
patent: 5530097 (1996-06-01), Pettit et al.
patent: 5543423 (1996-08-01), Zelle et al.
patent: 5565478 (1996-10-01), Kohn et al.
patent: 0 398 558 (1990-11-01), None
patent: 0 598 129 (1994-05-01), None
patent: 2 697 752 (1994-05-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 93/18210 (1993-09-01), None
patent: WO 94/10995 (1994-05-01), None
patent: WO 95/08994 (1995-04-01), None
patent: WO 95/19769 (1995-07-01), None
patent: WO 96/18401 (1996-06-01), None
patent: WO 96/40751 (1996-12-01), None
patent: WO 96/40752 (1996-12-01), None
Rose, W.C., “Taxol-Based Combination Chemotherapy and Other In Vivo Preclinical Antitumor Studies”,J. of the National Cancer Institute Monographs(15):47-53 (1993).
Holton, R.A., et al., “First Total Synthesis of Taxol. 1. Functionalization of the B Ring,”J. Am. Chem. Soc., 116:1597-1601 (1994).
Nicolaou, K.C., et al., “Total Synthesis of Taxol,”Nature, 367:630-634 (1994).
Kumar, N., “Taxol-induced Polymerization of Purifid Tubulin,”J. Biol. Chem. 256:10435-10441 (1981).
Rowinsky, E.K., et al., “Taxol: A Novel Investigational Antimicrotubule Agent,”J. Nat'l Cancer Inst., 82:1247-1259 (1990).
Schiff, P.B., et al., “Promotion of Microtubule Assembly in vitro by taxol,”Nature, 277:665-667 (1979).
McGuire, W.P., et al., “Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms,”Ann. Int. Med., 111:273-279 (1989).
Holmes, F., et al., “Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer,”J. Nat'l Cancer Inst., 83:1797-1805 (1991).
Kohn, E., et al., “A Pilot Study of Taxol, Cisplatin, Cyclophosphamide, and G-CSF In Newly Diagnosed Stage III/IV Ovarian Cancer Patients,”Am. Society for Clinical Oncology, 12:Abstract 814 (1993).
Bai, R., et al., “Structure-Activity Studies with Chiral Isomers and with Segments of the Antimitotic Marine Peptide Dolastatin 10,”Biochem. Pharmacology, 40:1859-1864 (1990).
Kohn, E.C., et al., “Dose-Intense Taxol: High Response Rate in Patients with Platinum-Resistant Recurrent Ovarian Cancer,”J. Nat'l Cancer Inst., 86:18-24 (1994). Abstract *814.
Leopold, W., et al., “Therapeutic Synergy of Trimetrexate (C1-898) in Combination with Doxorubicin, Vincristine, Cytoxan, 6-Thioguanine, Cisplatin, or 5-Fluorouracil Against Intraperitoneally Implanted P388 Leukemia,”NCI Monographs,(5):99-104 (1987).
Schabel, Jr., F.M., et al., “Quantitative Evaluation of Anticancer Agent Activity in Experimental Animals,”Pharmac Ther. A., 1:411-435 (1977).
Chou, T.-C., et al., “Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth” a Rational Approach to Clinical Protocol Design,J. of the National Cancer Institute, 86(20):1517-1524 (1994).
Knick, V.C., et al., “Vinorelbine Tartrate and Paclitaxel Combinations: Enhanced Activity Against In Vivo P388 Murine Leukemia Cells,”J. of the National Cancer Institute, 87(14):1072-1077 (1995).
Bissery, M.C., et al., “Docetaxel in combination with vinorelbine: Preclinical-clinical correlation,”Proc. Am. Soc. Clin. Oncol. 15 32 Meet, 48:(1996) Abstract 96-43670.
Beckwith, M., et al., “Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15,”J. Nat'l Cancer Inst., 85:483-488 (1993).
Freidinger, R., et al., “Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides,”J. Org. Chem.:104-109 (1982).
Galeotti, N., et al., “Formation of Oxazolines and Thiazolines in Peptides by the Mitsunobu Reaction,”Tetrahedron Letters, 33(20): 2807-2810 (1992).
Wipf, P., et al., “A Short, Stereospecific Synthesis of Dihydrooxazoles from Serine and Threonine Derivatives,”Tetrahedron Letters,p. 907-910 (1992).
Tully, W.R., et al., “2-(Oxadiazolyl)- and 2-(Thiazolyl)imidazo1,2-alpyrimidines as Agonist
Barlozzari Teresa
Haupt Andreas
BASF - Aktiengesellschaft
DeConti, Esq. Giulio A.
Goldberg Jerome D.
Lahive & Cockfield LLP
Lauro, Esq. Peter C.
LandOfFree
Dolastatin-15 derivatives in combination with taxanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dolastatin-15 derivatives in combination with taxanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dolastatin-15 derivatives in combination with taxanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3146582